It can inhibit the pathological excessive secretion of growth hormone, thyroid-stimulating hormone, gastrointestinal and pancreatic endocrine hormones; it can selectively reduce the blood flow and pressure of the portal vein and its collateral circulation, and reduce the pressure of varicose veins in the esophagus and gastric fundus; it can inhibit gallbladder emptying and have a therapeutic effect on pancreatic lesions; it can inhibit the secretion of gastric acid and gastrin, and improve the blood supply to the gastric mucosa; it can inhibit gastrointestinal motility.

Extract from the above information

Similar to the natural hormone arginine vasopressin, it has a longer duration of action after structural modification and has no side effects of pressor. Intravenous injection of 0.3 micrograms per kilogram of body weight can increase the activity of coagulation factor VIII in plasma by 2-4 times, while increasing von Willebrand antigen factor and releasing tissue plasminogen activator, shortening or normalizing bleeding time, and avoiding the risk of HIV and hepatitis virus infection caused by factor VIII preparations.

Similar to the natural hormone arginine vasopressin, it has a longer duration of action after structural modification and does not produce pressor side effects. Intravenous injection of 0.3 micrograms per kilogram of body weight can increase the activity of coagulation factor VIII in plasma by 2-4 times, increase von Willebrand antigen factor (vWF:Ag), and release tissue plasminogen activator (t-PA). It has an improving effect on prolonged bleeding time caused by uremia, cirrhosis, congenital or drug-induced platelet dysfunction, and can shorten or normalize bleeding time. The use of this product avoids the risk of HIV and hepatitis virus infection caused by the use of factor VIII preparations.